Aspen Pharmacare offers A$1.5 billion for troubled Sigma Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Aspen Pharmacare of South Africa has made a preliminary approach to acquire Sigma Pharmaceuticals for A$0.60 per share plus the assumption of net debt of A$785 million, valuing the Australian drugs manufacturer, marketer and distributor at A$1.49 billion (US$1.24 billion).